Sickle cell drug safety study ends early

NCT ID NCT05632354

First seen Mar 26, 2026 · Last updated May 09, 2026 · Updated 4 times

Summary

This study was designed to check the long-term safety of the drug GBT021601 in people with sickle cell disease who had already taken it in a previous study. It included 47 participants aged 6 months and older. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Aminu kano Teaching Hospital

    Kano, 700233, Nigeria

  • Inova Schar Cancer Institute

    Fairfax, Virginia, 22031, United States

  • Lagos University Teaching Hospital

    Lagos, 100254, Nigeria

  • Mississippi Center for Advanced Medicine

    Madison, Mississippi, 39110, United States

  • Our Lady of the Lake Hospital, Inc.

    Baton Rouge, Louisiana, 70808, United States

  • University College Hospital Ibadan

    Ibadan, Oyo/ibadan North, 200212, Nigeria

  • University Medical Center Inpatient Pharmacy

    New Orleans, Louisiana, 70112, United States

  • University Medical Center New Orleans

    New Orleans, Louisiana, 70112, United States

  • University of Texas Health Science Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.